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Abstract
Phosphodiesterase-4 (PDE4) inhibitors have recently been introduced to the
treatment of COPD and psoriatic arthritis. Microsomal prostaglandin E syn-
thase-1 (mPGES-1) is an inducible enzyme synthesizing PGE2, the most abun-
dant prostanoid related to inflammation and inflammatory pain. mPGES-1 is a
potential drug target for novel anti-inflammatory treatments aiming at an
improved safety profile as compared to NSAIDs. Here we investigated the effect
of the PDE4 inhibitor rolipram on the expression of mPGES-1 in macrophages;
and a potential mediator role in the process for MAP kinase phosphatase-1
(MKP-1) which is an endogenous factor limiting the activity of the proinflam-
matory MAP kinases p38 and JNK. The expression of mPGES-1 was decreased,
whereas that of MKP-1 was enhanced by rolipram in wild-type murine macro-
phages. Interestingly, rolipram did not reduce mPGES-1 expression in peritoneal
macrophages from MKP-1-deficient mice. A reduced phosphorylation of JNK,
but not p38 MAP kinase, was specifically associated with the decreased expres-
sion of mPGES-1. Accordingly, mPGES-1 expression was suppressed by JNK but
not p38 inhibitor. These findings underline the significance of the increased
MKP-1 expression and decreased JNK phosphorylation associated with the
downregulated expression of mPGES-1 by PDE4 inhibitors in inflammation.
Abbreviations
cAMP, cyclic AMP; COXs, cyclo-oxygenases; DMSO, dimethyl sulfoxide; EDTA,
ethylenediaminetetraacetic acid; FBS, fetal bovine serum; LPS, lipopolysaccharide;
MAPK, mitogen-activated protein kinase; MKP-1, mitogen-activated protein kinase
phosphatase 1; mPGES-1, microsomal prostaglandin E synthase-1; PBS, phosphate-
buffered saline; PDE4, phosphodiesterase-4; PGE2, prostaglandin E2.
Introduction
Phosphodiesterase-4 (PDE4) is a family of enzymes
expressed widely in immune cells, including macrophages.
PDE4 enzymes catalyze the degradation of cyclic AMP
(cAMP), modulate immune cell functions and have an
essential role in inflammation (Gantner et al. 1997; Essa-
yan 1999; Spina 2008). Specific inhibitors of PDE4 are
novel anti-inflammatory drugs, of which roflumilast was
lately introduced for the treatment of COPD and apremi-
last for plaque psoriasis and psoriatic arthritis (Lipworth
2005; Rabe 2011; Kavanaugh et al. 2015; Papp et al.
2015). Recently, PDE4 was also presented as a beneficial
drug target in B-cell lymphoma, based on the findings of
the anti-inflammatory properties of PDE4 inhibitors
(Cooney and Aguiar 2016).
Rolipram is a selective PDE4 inhibitor, the anti-inflam-
matory effects of which have been shown to be, at least
partly, dependent on the MAP kinase phosphatase-1
(MKP-1) (Lee et al. 2012; Korhonen et al. 2013; Patel et al.
2015). MKP-1 is an endogenous enzyme able to dephos-
phorylate and hence inactivate the proinflammatory MAP
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kinase p38 and JNK pathways (Franklin and Kraft 1997;
Chi et al. 2006; Hammer et al. 2006; Zhao et al. 2006;
Korhonen et al. 2011). MKP-1 expression is enhanced by
various inflammatory factors and serves as a limiting factor
against excessive inflammatory response (Korhonen and
Moilanen 2014). In addition, some anti-inflammatory
compounds further enhance MKP-1 expression or activity
leading to substantial suppression of inflammatory
responses (Kassel et al. 2001; Nieminen et al. 2010).
mPGES-1 has evoked interests as a potential anti-
inflammatory drug target since it was characterized in
1999 (Jakobsson et al. 1999; Samuelsson et al. 2007). It is
an inducible enzyme catalyzing the synthesis of prosta-
glandin E2 (PGE2), situated downstream of cyclo-oxyge-
nases (COXs) in the prostaglandin synthesis pathway. It
has been therefore suggested that by inhibiting the activity
or expression of mPGES-1, it would be possible to achieve
therapeutic effects comparable with COX-inhibitors (i.e.,
nonsteroidal anti-inflammatory drugs, NSAIDS) but with
less adverse effects (Samuelsson et al. 2007; Korotkova
and Jakobsson 2014; Koeberle and Werz 2015). Several
inhibitors of the activity of mPGES-1 have been character-
ized with a promising preclinical profile but unfortunately,
none of them is available for clinical use so far (Koeberle
and Werz 2015). Interestingly, the effects of mPGES-1
inhibitors may not be limited to inhibition of PGE2 syn-
thesis or classical effects of PGE2 in inflammation. For
instance, Idborg et al. (2013) recently reported that
genetic deletion of mPGES-1 shifted eicosanoid profiles
toward anti-inflammatory direction in activated macro-
phages by reducing PGE2 production and enhancing
PGD2 metabolites and some anti-inflammatory fatty acids.
Also, Raouf et al. (2016) reported that platelet activation
associated with inflammation is tempered in mPGES-1-
deficient mice as compared to wild-type animals.
Another pharmacological approach could be inhibition
of mPGES-1 expression in inflammatory conditions. The
regulation of mPGES-1 is not known in detail but it has
been shown to be suppressed by anti-inflammatory drugs
dexamethasone and aurothiomalate (Stichtenoth et al.
2001; Korotkova et al. 2005; Tuure et al. 2015). In addi-
tion, mPGES-1 expression has been reported to be upreg-
ulated by p38 and/or JNK MAP kinases. (Han et al. 2002;
Masuko-Hongo et al. 2004; Degousee et al. 2006; de Oli-
veira et al. 2008; Bage et al. 2010; He et al. 2016). On the
other hand, anti-inflammatory effects of the PDE4 inhibi-
tor rolipram (Korhonen et al. 2013), like those of dexam-
ethasone (Kassel et al. 2001; Abraham et al. 2006; Shipp
et al. 2010) and aurothiomalate (Nieminen et al. 2010)
have been shown to be mediated by enhanced expression
of the anti-inflammatory phosphatase MKP-1 which leads
to reduced activity of MAP kinases through dephosphory-
lation. We therefore aimed to study if the PDE4 inhibitor
rolipram downregulates the expression of mPGES-1 and if
MKP-1 is involved in mediating the effect.
There are no published reports on the effects of PDE4
inhibitors on the expression of mPGES-1 and neither
those on the role of MKP-1 in the expression of mPGES-
1. The knowledge about interactions of phosphorylated
MAP kinases and the expression of mPGES-1 is also lim-
ited. Therefore, we investigated the effects of the selective
PDE4 inhibitor rolipram on the expression of mPGES-1
and MKP-1 and on the (de)phosphorylation of MAP
kinases p38 and JNK in classically activated macrophages
using the J774 murine macrophage cell line. Moreover,
we tested the hypothesis that the effects of rolipram on
the expression of mPGES-1 could be mediated by MKP-1
by studying the effects of rolipram on peritoneal macro-
phages from MKP-1-deficient and corresponding wild-
type mice.
Materials and Methods
Cell culture
J774 mouse macrophages (American Type Culture Collec-
tion, Rockville Pike, MD, USA) were cultured at +37°C
in 5% CO2 atmosphere in Dulbecco’s Modified Eagle’s
medium (DMEM; Invitrogen, Paisley, UK) containing
10% (v/v) heat-inactivated fetal bovine serum (FBS),
100 U/mL penicillin, 100 lg/mL streptomycin and
250 ng/mL amphotericin B (all from Gibco, Wien, Aus-
tria). 2 9 105 cells per well were seeded on 24-well plates
and the cell monolayers were grown for 72 h to conflu-
ence prior to the experiments. SP600125 (Sigma-Aldrich
Inc., St. Louis, MO, USA) and BIRB796 (Axon Med-
Chem, Groningen, Netherlands) were dissolved in
dimethyl sulfoxide (DMSO) and rolipram (Axon Med-
Chem), dexamethasone (Orion Corp., Espoo, Finland)
and lipopolysaccharide (LPS) from Escerichia coli strain
0111:B4 (Sigma-Aldrich Inc.) in phosphate-buffered saline
(PBS). LPS and the compounds of interest in concentra-
tions indicated or the solvent were added to the cells in
fresh culture medium containing 10% FBS and the sup-
plements, and the final concentration of DMSO was
adjusted to 0.1% in all wells. Cells were further incubated
for the time indicated before collecting cellular proteins/
RNA and the culture medium.
Mouse peritoneal macrophages were harvested from
MKP-1-deficient and corresponding wild-type C57BL/6
mice originally generated in the laboratory of R. Bravo at
Bristol-Myers Squibb Pharmaceutical Research Institute
(Princeton, NJ, USA). Mice were bred at the University
of Tampere animal facility under standard conditions
(12:12 light:dark cycle, +22  1°C temperature, 50–60%
humidity), and food and water provided ad libitum.
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Animal experiments were carried out in accordance with
the legislation for the protection of animals used for sci-
entific purposes (Directive 2010/63/EU), and the study
was approved by the National Animal Experiment Board.
Peritoneal macrophages were obtained by peritoneal
lavage with sterile PBS supplemented with 0.2 mmol/L
ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich
Inc.). Cells were washed and seeded on 24-well plates
(1 9 106 cells/well) in RPMI medium supplemented with
2% FBS, 100 U/mL penicillin, 100 lg/mL streptomycin
and 250 ng/mL amphotericin B. Cells were incubated
overnight, washed and treated with the compounds of
interest for the time indicated.
Preparation of cell lysates and Western blot
analysis
At the indicated time-points, the culture medium was
removed from the cells. Cells were washed with ice-cold
PBS and solubilized in cold lysis buffer containing
10 mmol/L Tris–HCl, 5 mmol/L EDTA, 50 mmol/L
NaCl, 1% Triton X-100, 0.5 mmol/L phenylmethylsul-
fonyl fluoride, 1 mmol/L sodium orthovanadate, 20 lg/
mL leupeptin, 50 lg/mL aprotinin, 5 mmol/L sodium flu-
oride, 2 mmol/L sodium pyrophosphate and 10 lmol/L
n-octyl-b-D-glucopyranoside (all from Sigma-Aldrich
Inc.). After incubation for 15 min on ice, lysates were
centrifuged, and the supernatants were collected and
mixed in a ratio of 1:4, with SDS loading buffer
[62.5 mmol/L Tris–HCl, pH 6.8, 10% glycerol, 2% SDS,
0.025% bromophenol blue and 5% b-mercaptoethanol
(all from Sigma-Aldrich Inc)], and stored at 20°C until
analyzed. Equal amounts of protein (10 or 20 lg) were
loaded on a 12% SDS-polyacrylamide gel and separated
by electrophoresis. Proteins were transferred to nitrocellu-
lose membranes by dry electroblotting using iBlot gel
transfer stacks and the Invitrogen iBlot Device (Invitro-
gen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. After transfer, the membrane was blocked in
TBS/T [20 mmol/L Trisbase (pH 7.6), 150 mmol/L NaCl,
0.1% Tween-20] containing 5% non-fat milk for 1 h at
room temperature. For detection of phosphorylated pro-
teins, membranes were blocked in TBS/T containing 5%
BSA. Membranes were incubated overnight at +4°C with
primary antibody and for 1 h with secondary antibody,
and the chemiluminescent signal was detected by Image-
QuantTM LAS 4000 mini (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden). The chemiluminescent signal was
quantified with ImageQuant TL 7.0 Image Analysis Soft-
ware (GE Healthcare Bio-Sciences AB). Following anti-
bodies were used in the Western blot analysis: mPGES-1
antibody (AS-03031; Agrisera AB, Vännäs, Sweden), actin
antibody (sc-1616R, Santa Cruz Biotechnology, CA,
USA), JNK antibody (#9251, Cell Signaling Technology
Inc., Beverly, MA, USA) and polyclonal goat anti-rabbit
antibody (sc-2004; Santa Cruz Biotechnology), MKP-1
antibody (SAB2500331; Sigma-Aldrich Inc), p38 MAPK
antibody (ab27986; Abcam plc., Cambridge, UK), phos-
pho-p38 MAPK antibody (#9211, Cell Signaling Technol-
ogy Inc), and phospho-JNK antibody (#9251; Cell
Signaling Technology Inc).
RNA extraction and quantitative reverse
transcription polymerase chain reaction
(qRT-PCR)
At the indicated time-points, the culture medium was
removed, and cell homogenization and RNA extraction were
carried out using GenEluteTM Mammalian Total RNA Mini-
prep Kit (Sigma-Aldrich Inc.) according to the manufac-
turer’s instruction. Reverse transcription of RNA extracted
from J774 cells and from peritoneal macrophages to cDNA
was performed by TaqMan Reverse Transcription Reagents
(Applied Biosystems, Foster City, CA, USA) and Maxima
First strand cDNA synthesis kit for RT-qPCR (Thermo
Fisher Scientific, Waltham, MA, USA), respectively. Primers
and probes were purchased from Metabion (Martinsried,
Germany). Their sequences and concentrations were opti-
mized according to the manufacturer’s guidelines in Taq-
Man Universal PCR Master Mix Protocol part number
4304449 revision C (Applied Biosystems) and were as fol-
lows: mouse mPGES-1 CCTGGATACATTTCCTCGTTGTC
(forward, 300 nmol/L), GAAGGCGTGGGTTCAGCTT (re-
verse, 300 nmol/L), ACAGGCCGTGTGGTACACACCG
(probe, 150 nmol/L); mouse MKP-1 CTCCTGGTTCAAC
GAGGCTATT (forward, 300 nmol/L), TGCCGGCCTGG
CAAT (reverse, 300 nmol/L), CCATCAAGGATGCTGGAG
GGAGAGTGTT (probe, 150 nmol/L); and mouse GAPDH
GCATGGCCTTCCGTGTTC (forward, 300 nmol/L), GATG
TCATCATACTTGGCAGGTTT (reverse, 300 nmol/L) and
TCGTGGATCTGACGTGCCGCC (probe, 150 nmol/L).
Quantitative PCR was performed using TaqMan Universal
PCR Master Mix and ABI Prism 7500 sequence detection
system (Applied Biosystems). The PCR cycling parameters
were incubation at 50°C for 2 min, incubation at 95°C for
10 min, 40 cycles of denaturation at 95°C for 15 sec and
annealing and extension at 60°C for 1 min. A standard curve
method was used to estimate the relative mRNA levels.
When calculating the results, mPGES-1 and MKP-1 mRNA
levels were first normalized against GAPDH.
Statistics
Results are expressed as mean + standard error of the
mean (SEM). One-way ANOVA with Bonferroni’s postt-
est was performed using GraphPad InStat version 3.10 for
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Windows. Differences were considered significant at
*P < 0.05, **P < 0.01 and ***P < 0.001.
Results
An evident increase in the expression of mPGES-1 was
found when J774 macrophages were stimulated with LPS
(Fig. 1). The PDE4 inhibitor rolipram significantly inhib-
ited the expression of mPGES-1 mRNA and protein in
stimulated cells, which is an original finding. The gluco-
corticoid dexamethasone was used as a positive control
for inhibition of mPGES-1 expression (Stichtenoth et al.
2001) and it also decreased the expression of mPGES-1 as
expected.
To test the hypothesis that the inhibition of the expres-
sion of mPGES-1 by rolipram could be mediated by
MKP-1, we first measured the effects of rolipram on the
expression of MKP-1. Rolipram significantly increased
the expression of MKP-1 mRNA and protein both in the
absence and in the presence of LPS as compared to the
unstimulated cells (Fig. 2). Dexamethasone was used as a
positive control (Kassel et al. 2001) and it also enhanced
MKP-1 levels as expected.
MKP-1 is known to control the intensity of inflamma-
tion by dephosphorylating MAP kinase p38, JNK or both
depending on the cell type (Korhonen and Moilanen 2014).
Therefore, we measured the effect of rolipram on the levels
of phosphorylated p38 and JNK in LPS-stimulated murine
macrophages. Both p38 and JNK were rapidly phosphory-
lated when the cells were exposed to LPS (Fig. 3). Rolipram
significantly reduced the levels of phosphorylated JNK but
not the levels of phosphorylated p38 (Fig. 3). This suggests
that the effect of rolipram on the expression of mPGES-1 is
specifically mediated by attenuated phosphorylation of
MAP kinase JNK rather than p38.
Therefore, we next investigated the effects of a JNK
inhibitor compared to those of a p38 inhibitor on J774
macrophages. The JNK inhibitor SP600125 (Bennett et al.
Figure 1. Effects of the PDE4 inhibitor rolipram and dexamethasone on mPGES-1 expression in murine J774 macrophages. Cells were incubated
with bacterial lipopolysaccharide (LPS) and rolipram or dexamethasone (which was used as a control compound) for 24 h. mPGES-1 mRNA levels
were measured by quantitative RT-PCR and normalized against GAPDH mRNA levels (A). mPGES-1 protein expression was measured by Western
blot where actin was used as a loading control (B). mPGES-1 expression levels in unstimulated (control) cells were set as 1 and the other values
were related to that. Results are expressed as mean + SEM, n = 6–7 (A) and 5–6 (B). One-way ANOVA with Bonferroni’s post-test was performed
and statistical significance is indicated as **P < 0.01 and ***P < 0.001.
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2001) reduced the expression of mPGES-1 mRNA and
protein to a similar extent as rolipram (Fig. 4). In con-
trast, the p38 inhibitor BIRB796 (Kuma et al. 2005) did
not have a significant effect.
Finally, we wanted to investigate the causal role of
MKP-1 as a mediator of the observed drug effect by com-
paring the effect of rolipram on the expression of
mPGES-1 in peritoneal macrophages from MKP-1-defi-
cient and corresponding wild-type mice. Rolipram signifi-
cantly decreased the expression of mPGES-1 in peritoneal
macrophages from wild-type mice, but not in those from
MKP-1-deficient mice (Fig. 5), whereas mPGES-1 expres-
sion was higher in unstimulated MKP-1-deficient macro-
phages than in wild-type cells supporting the known role
of MKP-1.
In conclusion, this data suggests that the PDE4 inhibi-
tor rolipram decreases the expression of mPGES-1 by a
mechanism related to increased expression of MKP-1 and
decreased phosphorylation of the MAP kinase JNK in
classically activated macrophages.
Figure 2. Effects of rolipram and dexamethasone on the production of MKP-1 in murine J774 macrophages (A and B) and in mouse peritoneal
macrophages (C). Cells were incubated with rolipram or dexamethasone (which was used as a control compound) with and without bacterial
lipopolysaccharide (LPS) for 1 h. MKP-1 mRNA levels were measured by quantitative RT-PCR and normalized against GAPDH mRNA levels (A and
C). MKP-1 protein expression was measured by Western blot where actin was used as a loading control (B). MKP-1 expression levels in the
unstimulated (control) cells were set as 1 and the other values were related to that. Results are expressed as mean + SEM, n = 11–12 (A), 9 (B)
and 5–6 (C). One-way ANOVA with Bonferroni’s post-test was performed and statistical significance is indicated as *P < 0.05, **P < 0.01 and
***P < 0.001.
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Discussion
In this study, we found that rolipram enhanced the
expression of MKP-1 with a concomitant decrease in the
expression of mPGES-1. Furthermore, the inhibitory
effect on mPGES-1 expression seen in peritoneal macro-
phages from wild-type mice was abolished in cells from
MKP-1-deficient mice strongly suggesting that the anti-
inflammatory effect of rolipram on mPGES-1 expression
is indeed dependent of MKP-1. The results also indicate
that excessive mPGES-1 expression can be downregulated
by compounds which enhance MKP-1 in classically acti-
vated macrophages.
Rolipram is a prototypic selective inhibitor of PDE4 with
a promising preclinical profile, but the compound was
discarded from clinical development due to unfortunate
adverse effects (Zhu et al. 2001). Later, rolipram has been
widely used as a pharmacological tool in research focusing
on effects mediated via suppressed PDE4 activity and
enhanced intracellular cAMP levels. Recently, rolipram was
found to inhibit the expression of the proinflammatory
cytokine TNF-a with a concomitant increase in the expres-
sion of the anti-inflammatory phosphatase MKP-1 in mur-
ine macrophages and to attenuate carrageenan-induced
inflammatory paw edema in wild-type mice (Korhonen
et al. 2013). Both of these effects were abolished in MKP-1
knock-out mice proposing a role for MKP-1 as a mecha-
nism mediating anti-inflammatory effects of PDE4
inhibitors. This could be explained by the fact that the
MKP-1 promoter contains two cAMP-responsive elements
Figure 3. Effects of rolipram on the phosphorylation of MAP kinases p38 (A) and JNK (B). J774 cells were preincubated with the rolipram for 1 h
and stimulated with bacterial lipopolysaccharide (LPS) for 30 min. The levels of phosphorylated and total p38 and JNK were measured by Western
blot and the amounts of phosphorylated p38 and JNK were normalized against the total p38 and JNK, respectively. Levels of pp38 and pJNK in
the unstimulated (control) cells were set as 1 and the other values were related to that. Results are expressed as mean + SEM, n = 4 (A) and 6
(B). One-way ANOVA with Bonferroni’s post-test was performed and statistical significance is indicated as *P < 0.05, ***P < 0.001 and ns = not
significant.
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(CREs) (Kwak et al. 1994) which bind the transcription
factor CREB, and the expression of MKP-1 has been shown
to be enhanced by activated cAMP-PKA-CREB signaling.
In support of that, PDE4 inhibitors, including rolipram,
have recently been presented to enhance the anti-inflam-
matory effects of b2-agonists with a concomitant increase
in MKP-1 expression in airway smooth muscle cells and
murine macrophages (Patel et al. 2015; Ker€anen et al.
2016).
Increased intracellular cAMP is believed to mediate the
therapeutic effects of PDE4 inhibitors because they reduce
the enzymatic degradation of cAMP. Therefore, it is inter-
esting and seemingly contradictory to our results that ele-
vated cAMP levels triggered by activation of EP2
receptors have previously been reported to increase
mPGES-1 expression in RAW 264.7 macrophages (Diaz-
Munoz et al. 2012). That study proposed a positive feed-
back process for PGE2 production, but PDE4 inhibitors
or MKP-1 were not investigated. In this study, we found
that rolipram increased MKP-1 expression and reduced
mPGES-1 expression both in J774 macrophages and in
primary mouse peritoneal macrophages. Based on these
studies it is possible that the effects of cAMP on mPGES-
1 expression differ between cell lines or types. On the
other hand, the kinetics, intensity and intracellular com-
partmentalization of increased intracellular cAMP may be
different following activation of G-protein-coupled recep-
tors and following inhibition of cAMP degrading PDEs.
Another possibility is that increased intracellular cAMP
has two distinct and opposite effects on mPGES-1 expres-
sion: directly through activation of mPGES-1 promoter
and indirectly through increased MKP-1 expression. Yet,
our results cannot entirely exclude the possibility that the
effects of rolipram on MKP-1 and mPGES-1 could be
cAMP-independent.
The anti-inflammatory role of MKP-1 is suggested to
be based on dephosphorylation of MAP kinases p38 and/
or JNK depending on the cell type (Franklin and Kraft
1997; Franklin et al. 1998; Korhonen and Moilanen
2014). In addition, mPGES-1 expression has been
reported to be regulated by p38 and/or JNK kinases
depending on the cell type, stimulating agent, and
Figure 4. Effects of the selective JNK inhibitor SP600125 and the selective p38 inhibitor BIRB796 on mPGES-1 expression in J774 murine
macrophages. Cells were incubated with bacterial lipopolysaccharide (LPS) and SP600125 or BIRB796 for 24 h. mPGES-1 mRNA levels were
measured by quantitative RT-PCR and normalized against GAPDH mRNA levels (A). mPGES-1 protein expression was measured by Western blot
where actin was used as a loading control (B). mPGES-1 expression levels in the unstimulated (control) cells were set as 1 and the other values
were related to that. Results are expressed as mean + SEM, n = 5–7. One-way ANOVA with Bonferroni’s post-test was performed and statistical
significance is indicated as **P < 0.01, ***P < 0.001 and ns = not significant.
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signaling cascade concerned. On this account, we wanted
to elucidate if the MKP-1-dependent effect of rolipram
would limit the expression of mPGES-1 by dephosphory-
lating p38 or JNK in macrophages. Based on our results,
rolipram reduced the levels of phosphorylated JNK but
not p38 in association with the enhanced MKP-1 and
suppressed mPGES-1 expression. This suggests that the
downregulation of mPGES-1 expression by rolipram is
mediated via reduced phosphorylation of the JNK kinase.
Accordingly, JNK inhibitor was found to suppress the
expression of mPGES-1 in J774 macrophages to an extent
comparable with that of rolipram, whereas the specific
inhibitor of p38 did not have any significant effect. Apart
from our study, the dephosphorylation of JNK as a mech-
anism behind decreased expression of mPGES-1 has pre-
viously been presented in rat neonatal cardiomyocytes
(Degousee et al. 2006), mouse peritoneal macrophages
(Cardeno et al. 2014) and recently also in murine micro-
glial cells (He et al. 2016), which findings support our
current results.
mPGES-1 expression is enhanced by a variety of
inflammatory factors including IL-1b, TNF-a, and LPS,
the latter of which was also used in this study. Early
growth response protein 1 (EGR-1) and nuclear factor
kappa B (NF-jB) are regarded as key transcription factors
for induction of mPGES-1 in inflammation but also other
factors have been identified (Koeberle and Werz 2015).
One of those is AP-1 (Moon et al. 2005; Jungel et al.
2007) which is activated by JNK and could explain the
JNK-mediated enhancement of mPGES-1 found in this
study. Another explanation could base on the finding in
cardiomyocytes (Degousee et al. 2006) that JNK stabilizes
mPGES-1 mRNA leading to enhanced mPGES-1 protein
levels. Further studies are, however, needed to understand
the detailed molecular mechanisms linking JNK activity
to enhanced mPGES-1 expression.
In summary, our results show that the PDE4 inhibitor
rolipram inhibits the expression of mPGES-1 in classically
activated macrophages. That is a novel anti-inflammatory
activity associated with PDE4 inhibitors, which likely
Figure 5. Effects of rolipram on the expression of mPGES-1 in
peritoneal macrophages from wild-type and MKP-1-deficient (knock-
out, KO) mice. Peritoneal macrophages were incubated with bacterial
lipopolysaccharide (LPS) or the combination of LPS and rolipram for
24 h. mPGES-1 mRNA levels were measured by quantitative RT-PCR
and normalized against GAPDH mRNA levels. mPGES-1 mRNA levels
in unstimulated cells from wild-type mice were set as 1, and the other
values were related to that. Results are expressed as mean + SEM,
n = 4. One-way ANOVA with Bonferroni’s post-test was performed
and statistical significance is indicated as ***P < 0.001, #P = 0.0286
versus unstimulated cells from wild-type mice and ns = not
significant.
Figure 6. Proposed mechanism of the downregulation of mPGES-1
by the PDE4 inhibitor rolipram. The PDE4 inhibitor rolipram was
discovered to inhibit the expression of mPGES-1, which is an enzyme
closely associated with inflammation and inflammatory pain. The
results suggest that the inhibitory effect is mediated via increased
expression of MKP-1 and decreased phosphorylation of MAP
kinase JNK. PDE4 = Phosphodiesterase 4; MKP-1 = MAP kinase
phosphatase 1; JNK = Jun N-terminal kinase; mPGES-1 = Microsomal
prostaglandin E synthase-1.
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contributes to their clinical efficacy. The mechanism in
question was found to be mediated via increased expres-
sion of MKP-1 and decreased phosphorylation (i.e.,
reduced activity) of the MAP kinase JNK (Fig. 6). These
results also underline the significance of MKP-1 and JNK
as targets for development of new anti-inflammatory
treatments targeting conditions complicated with exces-
sive expression of mPGES-1.
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